Antigona Trofor

Clinica de Pneumologie Iaşi

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Constantine Vardavas

Hellenic Cancer Society

Esteve Fernández

Institut Català d'Oncologia

Ute Mons

German Cancer Research Center

Geoffrey T. Fong

University of Waterloo

Tibor Demjén

Hungarian Institute of Occupational Health

Witold Zatoński

The Maria Sklodowska-Curie National Research Institute of Oncology

Christina N Kyriakos

Imperial College London

Yannis Tountas

National and Kapodistrian University of Athens

Krzysztof Przewoźniak

The Maria Sklodowska-Curie National Research Institute of Oncology

Pete Driezen

University of Waterloo

Cooperative Institutions

Grigore T. Popa University of Medicine and Pharmacy

Clinica de Pneumologie Iaşi

Iuliu Hațieganu University of Medicine and Pharmacy

European Network for Smoking and Tobacco Prevention

Clinical Emergency Hospital Bucharest

University of Crete

Carol Davila University of Medicine and Pharmacy

National and Kapodistrian University of Athens

University of Waterloo

Instituto de Salud Carlos III

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Exploring the ESKAPE maze: Pneumonias, resistance and therapeutic perspectives

Pneumologia (2023)

Ioana Stoian A Antal Paula Vasilache Antohi Victoria Țău Adriana Loredana Pintilie

Abstract The article explores drug-resistant bacteria within the ESKAPE group, commonly associated with nosocomial infections, focusing on the resistance mechanisms of Acinetobacter baumannii and Klebsiella pneumoniae. The study delves into various β-lactamase enzymes and resistance mechanisms exhibited by ESKAPE bacteria, shedding light on the challenges posed by carbapenem-resistant infections. Notably, the article underscores the ongoing need for research to develop more effective treatments and address the persistent challenges associated with drug resistance in the context of nosocomial infections. The examination of this subset of bacteria aims to contribute to a comprehensive understanding of their resistance mechanisms and provides insights into the difficulties encountered in treating infections with carbapenem-resistant pathogens. The article serves as a valuable resource for clinicians, researchers and policymakers, offering a detailed perspective on the current state of drug resistance among nosocomial pathogens and advocating for continuous research to enhance treatment efficacy in the face of evolving challenges.

10.2478/pneum-2024-0020

Cite

Citations (0)

[Extreme solutions for those who do not succeed to quit smoking. About smokeless tobacco and harm reduction].

PubMed (2008)

Antigona Trofor V Eşanu Elena-Iuliana Frăsilă

Although in the last two decades, intensified tobacco control measures have increased access to smoking cessation services worldwide and pharmacological therapy in the field had enlarged spectrum and has higher efficiency, yet, long term abstinence rate is no more than 20-25%. Only 70% of smokers are willing to quit and only 10% succeed for good. The rest of 60% plus 30% not even willing to quit will balance between new attempts to quit, new failures to quit and continuing smoking, mainly cigarettes. Among them, many heavy smokers, highly nicotine addicted, unable to quit, even if strongly motivated to. Harm reduction concept is proposing alternatives to classic cigarettes smoking, which is the most dangerous modality of tobacco products consumption. Such alternatives try to minimize as much as possible harm induced by tobacco smoking,by reducing carcinogenic and toxic compounds in tobacco products. Overview of smokeless tobacco types is given, with health risks and consumption particularities in each case. Scientific community in the field's opinions are presented from the perspective of finding ways to save as many lives as possible of smokers unable to quit and to change actual status quo. As part of experts predict continuous increasing smoking prevalence in the future unless competitive alternatives to cigarettes smoking are arising, such alternatives can be temporarily helpful, in order to assist all categories of smokers to avoid tobacco smoke (most dangerous form of smoking) exposure.

harm reduction

Snus

Consumption

Nicotine replacement therapy

Source

Cite

Citations (2)

Smoking cessation for free: outcomes of a study of three Romanian clinics

Open Medicine (2016)

Antigona Trofor Milena Adina Man Corina Mărginean Dumitru Filipeanu Antigona Trofor

In 2007, Romania implemented a national program for smoking cessation, providing medication and counseling, entirely for free. The present study focuses on the results of the program among participating smokers treated in three smoking cessation centers from three main cities of Romania: Iasi, Targu Mures and Cluj. Telephone interviews of 832 subjects from three databases of the Romanian cessation clinics of Iasi, Cluj and Targu Mures cities were conducted. These interviews were based on a standard Romanian guideline follow-up questionnaire. At 3 months follow up, abstinence was quite high (53.4%); at 12 months post quit date the study found 18.6% still abstinent subjects. More severely addicted smokers have quit with varenicline and the most difficult category of patients was represented by heavy smokers with respiratory co-morbidities. 61.5% of smokers and 97.2% of non-smokers were willing to receive relapse prevention counseling. Many subjects achieved a long duration partial abstinence (154 days ± 180 SD abstinence days). This is the first study in Romanian smoking cessation centers to analyze the long term impact of fully reimbursed smoking cessation, covering three months pharmacotherapy and counseling. Providing smoking cessation for free had a positive long term impact on program participants.

Varenicline

Guideline

Romanian

Nicotine replacement therapy

Pharmacotherapy

10.1515/med-2016-0098

Cite

Citations (126)

Tobacco control and cessation in Romania – a situation analysis

Tobacco Prevention & Cessation (2016)

Antigona Trofor Cornel Radu-Loghin

The European Network for Smoking and Tobacco Prevention (ENSP) has been active in tobacco control since 1997 and for the last 19 years has been playing an important role in setting and influencing policies at a European and international level.Spearheading ENSP activities and projects are national representatives, organisations, academics, doctors, lawyers, health care professionals, experts and activists who always worked together to fulfil the objectives and mission of ENSP.ENSP is the only truly pan-European network active in tobacco control being the key grassroots organisation in implementing the World Health organization Framework Convention on Tobacco Control (WHO-FCTC) at a European level.This was acknowledged by the WHO-FCTC -Conference of Parties during the session in Uruguay (November 2010) when ENSP received FCTC observer status.It is almost impossible to talk about FCTC in Europe without mentioning the involvement of at least one ENSP member.This united and collective effort is the essence, the heart and soul of the "Network" concept: each link makes the chain stronger; each node adds value to the structure.This added value is not only found in the strength of the partnership but also on a scientific level in everything ENSP does: its core activities, its EU projects but also its new scientific journal, "Tobacco Prevention & Cessation".Tobacco consumption remains the single largest avoidable cause of premature death in Europe, responsible for 700,000 deaths every year, and is the most significant cause of health inequalities.It is an interesting time for our work in tobacco control, as the world recognises that the most effective policies are those based on scientific studies and solid evidence.Therefore, this year the conference is dedicated to three main topics: reSearCh -Research and science represent the base for lobby and advocacy activities.On 5th April, a special session is dedicated to the European research and Public Health Projects dealing with different tobacco control topics.In all those projects, ENSP is acting as a knowledge and networking hub, being a real support for researchers and partners involved in the projects' implementation.PreveNTioN -Next year ENSP celebrates 20 years of activities dedicated mainly to prevent tobacco consumption in Europe.During the conference, a series of workshops, plenary and parallel sessions aim to highlight its accomplishments based on constant guidance resulting from WHO FCTC and MPOWER strategies.TreaTmeNT -Wednesday April 6th is fully dedicated to the WHO-FCTC Art.14's implementation in Europe and we bring together, in a special training session, more than 50 experts from Armenia, Georgia, Romania, Russia and Ukraine, partner countries under the EPACTT Project developed in partnership with Global Bridges -Healthcare Alliance for Tobacco Dependence Treatment.The above-mentioned topics demonstrate the diversity and complexity of our Network, which is dedicated to tobacco control in Europe.Furthermore, the International Society for the Prevention of Tobacco Induced Diseases has joined forces by sponsoring two symposiums on Thursday 7 April, reinforcing the importance of academic and scientific research in our work.Bringing together more than 170 experts from over 30 countries, this Conference is a new step ahead in accomplishing our two top priority objectives as stated in our Statute: • To have the WHO-Framework Convention on Tobacco Control implemented in Europe by 2020 • To reduce the prevalence of tobacco use in Europe to below 5% by 2040.During the conference, as you discover and meet special guests and speakers from the Academic and European Institutions, World Health Organization, national authorities and well known non-governmental organisations involved in tobacco control at regional, national and international level, we hope you have the chance to share your experiences and insights pertaining to various facets of tobacco control.On behalf of ENSP members and Secretariat, we are honoured to invite you to our Tobacco Control Conference in Brussels, the capital city of Belgium and Europe, and would like to thank you, as well as all the presenters, without whom this event would not be possible, for your work, your dedication and your loyalty.eNSP Board aNd SeCreTariaT

10.18332/tpc/62408

Cite

Citations (1)

Contribution of Bronchoscopic Examination in Diagnosis of Congenital Tracheo-Broncho-Pulmonary Malformations

DOAJ (DOAJ: Directory of Open Access Journals) (2010)

Antigona Trofor Ramona Miron Antigona Trofor Mihaela Diana Ciobanu

Congenital malformations

Source

Cite

Citations (0)

Correlates of the support for smoke-free policies among smokers: A cross-sectional study in six European countries of the EUREST-PLUS ITC EUROPE SURVEYS

Tobacco Induced Diseases (2019)

Marcela Fu Yolanda Castellano Olena Tigova Ute Mons Thomas K Agar

This report describes the support for smoke-free policies in different settings among smokers in six European countries and the relationship between their opinions about the places where smoking should be banned and their beliefs about the harms of secondhand smoke to non-smokers.A cross-sectional survey (the ITC 6 European Country Survey, part of the EUREST-PLUS Project) was conducted using nationally representative samples of adult smokers in Germany, Greece, Hungary, Poland, Romania and Spain (n=6011). We describe the prevalence of agreement and support for smoke-free policies in different settings according to sociodemographics, smoking characteristics and beliefs about the danger of secondhand smoke to non-smokers.There was high agreement with smoking regulations in cars with preschool children and in schoolyards of primary/secondary schools (>90% overall) and low agreement with banning smoking in outdoor terraces of bars/pubs (8.6%; 95%CI: 7.5%-9.8%) and restaurants (10.1%; 95%CI: 8.9%-11.4%). The highest support for complete smoking bans inside public places came from smokers in Poland, among women, people aged ≥25 years, who had low nicotine dependence, and who tried to quit smoking in the last 12 months. About 78% of participants agreed that tobacco smoke is dangerous to non-smokers, ranging from 63.1% in Hungary to 88.3% in Romania; the highest agreement was noted among women, the 25-54 age groups, those with higher education, low cigarette dependence, and those who tried to quit in the last 12 months. The support for complete smoking bans in public places was consistently higher among smokers who agreed that secondhand smoke is dangerous to non-smokers.Smokers in six European countries declared strong support for smoke-free policies in indoor settings and in settings with minors but low support in outdoor settings, particularly leisure facilities. More education is needed to increase the awareness about the potential exposure to secondhand smoke in specific outdoor areas.

Cross-sectional study

Secondhand Smoke

Smoking ban

Smoking prevalence

Nicotine replacement therapy

Nicotine dependence

10.18332/tid/103918

Cite

Citations (15)

Smoking and post-COVID-19 syndrome: An overview

Tobacco Prevention & Cessation (2024)

Oana Elena Melinte Daniela Robu Popa Antigona Trofor

2019-20 coronavirus outbreak

Pandemic

10.18332/tpc/194400

Cite

Citations (0)

Carbon monoxide in smokers versus nonsmokers: Usefulness for everyday pulmonary disease clinical practice

Ramona Miron Daniela Bucur Antigona Trofor Maria Mădălina Bodescu Adina Mihailovici

Introduction Carbon monoxide (CO) is a biomarker of certain tobacco exposure, yet high levels appear in airway inflammation, environmental pollution or passive smoking. Aim To evaluate carbon monoxide levels in smokers versus nonsmokers and to correlate it with clinical and biological profile of the two groups, in an everyday pulmonary disease clinical practice. Material and method A group of 57 smokers and a control group of 54 non smokers were assessed age, gender, medical history, smoking status, cigarette consumption (packs-year), Fagerstrom nicotine dependence score and passive smoking, by a standard questionnaire . Lab diagnosis determined serum cholesterol, triglycerides and creatinine and carbon monoxide in exhaled air, in both groups. Statistic analysis and correlations of parameters was done, according to smoking status. Results Age average was lower in smokers (44.72)vs.48.06 in nonsmokers. Smokers were mean 30.33 ±15.07 SD packs-year consumers in men and 13.26 ± 9.56 SD in women, with high Fagerstrom scores in men ( p= 0.018 ), more frequent respiratory co-morbidities (p= 0.001 ) and a p= 0.045 for passive smoking. CO values were higher in male smokers ( p=0.002 ); mean CO in nonsmokers was 0.24 ± 1.37 SD. Smokers with high CO levels had higher serum creatinine( r=0,39 p=0,002). Higher cholesterol ( r= 0.42, p=0.002 ) and trigliceride( r=-0,28 p=0,033 ) were found in smokers with respiratory diseases. Conclusions Women had lower CO levels in both groups. Smokers with respiratory disease had higher levels of: serum creatinine, cholesterol and triglicerides, exhaled CO, passive smoking.

Passive smoking

Smoking history

Cite

Citations (0)

Profile of carcinogenic polycyclic aromatic hydrocarbons in relation with smoking status in COPD patients

Tobacco Prevention & Cessation (2023)

Antigona Trofor Ioana Buculei Mona Elisabeta Dobrin Cristina Vicol Daniela Robu Popa

reports of data from original research.• Policy Case Studies -brief articles on policy development at a regional or national level.• Study Protocols -Articles describing a research protocol of a study.• Methodology Papers -Papers that present different methodological approaches that can be used to investigate problems in a relevant scientific field and to encourage innovation.• Tobacco Industry Monitoring Letters -brief articles on tobacco industry tactics.

10.18332/tpc/172643

Cite

Citations (0)

Survival patients with pulmonary metastases in breast cancer neoplasia

Man Milena Cosmina Ioana Bondor Ioana Berindan‐Neagoe Monica Pop Antigona Trofor

Breast cancer is one of the most frequent neoplasia in women (27% of the total types of cancer). It represents the second cause of death in the USA after pulmonary cancer. We conducted a survey from January 2000 to December 2005 on 120 patients admitted in Cluj-Napoca Oncology Institute and Leon Daniello Pneumology Clinical Hospital. We introduced in the study patients diagnosed with breast carcinoma and pulmonary metastases, we analyzed risk factor and evolution of the diseases with survival function calculated since breast cancer diagnosis, and the other calculated since pulmonary metastases. Age of the patients over 60 years (p=0.01), urban areas (p=0.048), smoking (p=0.001), time between the first symptoms and the doctor' presentation (more than 1 year) was significant statistic in both survival (p=0.005 and p=0.003). Good performance status (p=0.03), the stage of the disease at presentation (p=0.004), type of metastasis, good risk class (p=0.0004), response at the treatment (only 5% had complete response) influence the survival calculated from the breast cancer diagnosis (69.15% at 1 year, 17.02% at 5 years, 4.26% at 10 years) and the survival calculated from the moment of pulmonary metastases (32.53% at 1 year, 4.82% at 5 years, 2.41% at 10 years). Mathematics and statistic analysis were very important in evaluation and validation of prognostic factors of disease, because the doctor can choose the best treatment for each patient, can compare the therapeutic strategy in similar situation and can discover precocious recurrence of neoplasia.

Breast carcinoma

Source

Cite

Citations (0)